Jonathan Goldin1, Robert Elashoff2, Hyun J Kim1, Xaiohong Yan2, David Lynch3, Diane Strollo4, Michael D Roth5, Philip Clements5, Daniel E Furst5, Dinesh Khanna5, Srainnapha Vasunilashorn1, Gang Li6, Donald P Tashkin7. 1. Department of Radiologic Sciences, School of Public Health, University of California Los Angeles, Los Angeles, CA. 2. Department of Biomathematics , School of Public Health, University of California Los Angeles, Los Angeles, CA. 3. Department of Radiologic Sciences, National Jewish Hospital, Denver, CO. 4. University of Pittsburgh School of Medicine, Pittsburgh, PA. 5. Department of Medicine, School of Public Health, University of California Los Angeles, Los Angeles, CA. 6. Department of David Geffen School of Medicine, and the Department of Biostatistics, School of Public Health, University of California Los Angeles, Los Angeles, CA. 7. Department of Medicine, School of Public Health, University of California Los Angeles, Los Angeles, CA. Electronic address: dtashkin@mednet.ucla.edu.
Abstract
BACKGROUND: The Scleroderma Lung Study (SLS) demonstrated significant treatment-associated improvements in pulmonary function and symptoms when patients with scleroderma-related interstitial lung disease (SSc-ILD) were treated with a 1-year course of cyclophosphamide (CYC) in a randomized, double-blinded, placebo-controlled clinical trial. This study examined thoracic high-resolution CT (HRCT) scans obtained during the SLS for treatment-associated changes over time. METHODS:Ninety-eight of the 158 subjects (CYC group, 49 subjects; placebo group, 49 subjects) participating in the SLS underwentthoracic HRCT scans both at baseline and after 12 months of treatment, which were available for analysis. Two independent radiologists visually scored the baseline HRCT scans for the presence of ground-glass opacities (GGOs), fibrosis (FIB), and honeycomb cysts (HCs) on a scale of 0 to 4. The treatment effect at 12 months was assessed by a blinded comparison of baseline and follow-up scans for evidence of stability and improvement (not worse) or deterioration (worse). RESULTS: At the end of treatment, FIB was significantly worse in the placebo treatment group than in the CYC treatment group (p = 0.014). Furthermore, differences in the 12-month change in FIB between the CYC and placebo groups correlated significantly with other outcome measures, including the 12-month changes in FVC (p < 0.05), total lung capacity (p < 0.05), and dyspnea (p < 0.001) scores. However, no differences were noted between the two groups with respect to changes in either GGOs or HCs. CONCLUSIONS: A 1-year course of treatment of SSc-ILD with CYC was associated with treatment-related changes in FIB scores on HRCT scans, which correlated with other measures of treatment response. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00004563.
RCT Entities:
BACKGROUND: The Scleroderma Lung Study (SLS) demonstrated significant treatment-associated improvements in pulmonary function and symptoms when patients with scleroderma-related interstitial lung disease (SSc-ILD) were treated with a 1-year course of cyclophosphamide (CYC) in a randomized, double-blinded, placebo-controlled clinical trial. This study examined thoracic high-resolution CT (HRCT) scans obtained during the SLS for treatment-associated changes over time. METHODS: Ninety-eight of the 158 subjects (CYC group, 49 subjects; placebo group, 49 subjects) participating in the SLS underwent thoracic HRCT scans both at baseline and after 12 months of treatment, which were available for analysis. Two independent radiologists visually scored the baseline HRCT scans for the presence of ground-glass opacities (GGOs), fibrosis (FIB), and honeycomb cysts (HCs) on a scale of 0 to 4. The treatment effect at 12 months was assessed by a blinded comparison of baseline and follow-up scans for evidence of stability and improvement (not worse) or deterioration (worse). RESULTS: At the end of treatment, FIB was significantly worse in the placebo treatment group than in the CYC treatment group (p = 0.014). Furthermore, differences in the 12-month change in FIB between the CYC and placebo groups correlated significantly with other outcome measures, including the 12-month changes in FVC (p < 0.05), total lung capacity (p < 0.05), and dyspnea (p < 0.001) scores. However, no differences were noted between the two groups with respect to changes in either GGOs or HCs. CONCLUSIONS: A 1-year course of treatment of SSc-ILD with CYC was associated with treatment-related changes in FIB scores on HRCT scans, which correlated with other measures of treatment response. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00004563.
Authors: Ioannis Pakas; John P A Ioannidis; Katerina Malagari; Fotini N Skopouli; Haralampos M Moutsopoulos; Panayiotis G Vlachoyiannopoulos Journal: J Rheumatol Date: 2002-02 Impact factor: 4.666
Authors: J Fujita; T Yoshinouchi; Y Ohtsuki; M Tokuda; Y Yang; I Yamadori; S Bandoh; T Ishida; J Takahara; R Ueda Journal: Ann Rheum Dis Date: 2001-03 Impact factor: 19.103
Authors: Demosthenes Bouros; Athol U Wells; Andrew G Nicholson; Thomas V Colby; Vlasis Polychronopoulos; Panos Pantelidis; Patricia L Haslam; Dimitris A Vassilakis; Carol M Black; Roland M du Bois Journal: Am J Respir Crit Care Med Date: 2002-06-15 Impact factor: 21.405
Authors: Beth Wallace; Suzanne Kafaja; Daniel E Furst; Veronica J Berrocal; Peter A Merkel; James R Seibold; Maureen D Mayes; Dinesh Khanna Journal: Rheumatology (Oxford) Date: 2015-02-09 Impact factor: 7.580
Authors: Elizabeth R Volkmann; Donald P Tashkin; Myung Sim; Ning Li; Ellen Goldmuntz; Lynette Keyes-Elstein; Ashley Pinckney; Daniel E Furst; Philip J Clements; Dinesh Khanna; Virginia Steen; Dean E Schraufnagel; Shiva Arami; Vivien Hsu; Michael D Roth; Robert M Elashoff; Keith M Sullivan Journal: Ann Rheum Dis Date: 2018-11-08 Impact factor: 19.103
Authors: Dinesh Khanna; James R Seibold; Athol Wells; Oliver Distler; Yannick Allanore; Chris Denton; Daniel E Furst Journal: Curr Rheumatol Rev Date: 2010-05-01
Authors: Jonathan G Goldin; Grace Hyun J Kim; Chi-Hong Tseng; Elizabeth Volkmann; Daniel Furst; Philip Clements; Matt Brown; Michael Roth; Dinesh Khanna; Donald P Tashkin Journal: Ann Am Thorac Soc Date: 2018-11
Authors: H G Kim; D P Tashkin; P J Clements; G Li; M S Brown; R Elashoff; D W Gjertson; F Abtin; D A Lynch; D C Strollo; J G Goldin Journal: Clin Exp Rheumatol Date: 2010-11-03 Impact factor: 4.473
Authors: Elizabeth R Volkmann; Donald P Tashkin; Ning Li; Daniel E Furst; Philip J Clements; Robert M Elashoff Journal: Rheumatology (Sunnyvale) Date: 2015-06-30